The final part of Dong et al.’s study [70] concentrated on qPCR analysis of 60 HER2+ BC tumour tissues from 30 chemoresistant and 30 chemotherapy-sensitive patients, and results indicated higher TINCR activity in chemoresistant patients, who subsequently experienced worse overall survival rate. This evidence concerns the gene ERBB2 and breast cancer.